Last reviewed · How we verify
Cytarabine-Idarubicin Association — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Cytarabine-Idarubicin Association (Cytarabine-Idarubicin Association) — French Innovative Leukemia Organisation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cytarabine-Idarubicin Association TARGET | Cytarabine-Idarubicin Association | French Innovative Leukemia Organisation | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cytarabine-Idarubicin Association CI watch — RSS
- Cytarabine-Idarubicin Association CI watch — Atom
- Cytarabine-Idarubicin Association CI watch — JSON
- Cytarabine-Idarubicin Association alone — RSS
Cite this brief
Drug Landscape (2026). Cytarabine-Idarubicin Association — Competitive Intelligence Brief. https://druglandscape.com/ci/cytarabine-idarubicin-association. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab